Kite Reports P-II Study (ALYCANTE) Results of Yescarta (axicabtagene ciloleucel) for Relapsed/Refractory Large B-Cell Lymphoma
Shots:
- The P-II study evaluated Yescarta as 2L therapy vs SoC in 62 patients with r/r LBCL deemed ineligible for HDCT & ASCT. The study was led & sponsored by the French collaborative group LYSA/LYSARC
- The study met its 1EPs & showed a complete metabolic response (71% vs 12%) at 3mos., 59.7% remained in CMR at 6mos., best OR (91.9%) & CR rates (82.3%), m-PFS from infusion (11.8mos.) after a median follow-up of 12mos., 48.8% were alive and progression-free at 12mos.
- m-OS (not reached), OS was 78.3% at 12mos. & showed an acceptable safety profile in this population considered unfit for HDCT/ASCT while 8.1% & 14.5% experienced grade 3-4 CRS or ICANS, respectively. The results were published in Nature Medicine
Ref: Kite | Image: Kite
Related News:- Kite Reports P-III Study (ZUMA-7) Results of Yescarta for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
